CD9 and breast cancer: Moreover, clinically relevant exosomes isolated with anti-CD9 or anti-CD63 antibodies and then detected with anti-HER2 revealed a 14–35% tumor-specific exosomes from breast cancer patient serums, which potentially could be used as non-invasive diagnostic method or even used to detect disease progression (81).